HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the company's credit card-sized ECG device can accurately identify heart attack risk in patients presenting with chest pain.
The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. The AUC rose to 92.9% when a personal, symptom-free baseline ECG was available for comparison. AUC is a measure of a test's ability to distinguish between those with and without a condition, with 100% being perfect.
The company said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025.
The HeartBeam System is the first cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
The study's findings could have significant implications for the early detection and management of heart attacks, potentially reducing time to treatment and improving outcomes. The ability to use a portable device to accurately assess heart attack risk in the field or at home could transform cardiac care, especially in remote or underserved areas.
For more information, the full press release is available at https://ibn.fm/ainxV. HeartBeam's cleared indications for use can be found at https://www.heartbeam.com/indications.
